An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * First Successful Clinical Trial with Anti-CD40L Antibody is Completed On October 29, a potentially major advancement for type 1 diabetes treatment was announced by the University of Miami Diabetes Research Institute (UM-DRI), in collaboration with the University of Chicago, regarding the...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Treatment of Hypertension On October 15, Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two phase III Trials in MASH for Survodutide On October 8, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Priority Review Granted for HER2-low or HER2-ultralow Metastatic Breast Cancer Treatment On October 1, AstraZeneca and Daiichi Sankyo announced that its supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TEPEZZA Receives Approval in Japan to Treat TED On Sept. 24, Amgen announced that TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neuroendocrine Tumor Treatment Data Presented by Exelixis On September 16, Exelixis announced updated and final data from CABINET, a Phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Study Data Support Efficacy of Treatment for Vasomotor Symptoms Associated with Menopause As reported in the Sept. 6 Pharma Fridays, Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glytec Expands Global Collaboration with Roche to Revolutionize Hospital Diabetes Management Transforming Global Hospital Diabetes Management On August 27, Glytec, announced an expansion of its collaboration with Roche, that will allow the use of Glytec’s software in connection with Roche’s smart-device...
